SCENESSE approved for EPP in Canada
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Clinuvel Pharmaceuticals Limited has announced that SCENESSE® has received approval from Health Canada for the treatment of erythropoietic protoporphyria (EPP), a rare metabolic disorder. The approval allows Clinuvel to market SCENESSE® in Canada, recognizing its compliance with Canadian drug regulations. Dr. Dennis Wright, Clinuvel’s Chief Scientific Officer, highlighted the drug's long-term safety profile and the extensive data supporting its clinical benefits.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL publicly files 20-F to U.S. SEC
- CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
- FDA relaxes SCENESSE postmarketing requirement
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
- Final EMA scientific advice for pivotal Phase III vitiligo
Later from Clinuvel Pharmaceuticals
- CLINUVEL strategic reorganisation to refocus on U.S. markets
- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
- Update - SCENESSE in vitiligo
- Commercial update on vitiligo
- A decade of profitability provides U.S. expansion foundation
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals